Patents by Inventor Johannes Roth
Johannes Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11267854Abstract: The present invention relates to mutants of S100A12 having at least one mutation in the high-affinity calcium binding hand or the low-affinity calcium binding hand or the zinc binding region. The present invention also relates to methods of detecting S100A12 dimers in a sample as well as methods of diagnosis using the S100A12 mutant of the invention, as well as to diagnostic compositions and kits comprising such an S100A12 mutant. The present invention further relates to a method of generating an antibody that specifically binds to an S100A12 dimer using the S100A12 mutant of the invention, as well as to an antibody that specifically binds to an S100A12 dimer.Type: GrantFiled: July 18, 2017Date of Patent: March 8, 2022Assignee: Westfaelische Wilhelms-Universitaet MuensterInventors: Johannes Roth, Thomas Vogl
-
Patent number: 11253570Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-?B-associated postnatal inflammatory disorder.Type: GrantFiled: November 6, 2017Date of Patent: February 22, 2022Assignees: Medizinische Hochschule Hannover (MHH), Westfalische Wilhelms-Universität MünsterInventors: Dorothee Viemann, Johannes Roth, Thomas Vogl
-
Publication number: 20210247407Abstract: The present invention relates to a method of stratifying a subject having no symptoms of acute tonsillitis for tonsillectomy or tonsillotomy, to a method of diagnosing recurrent tonsillitis in a subject having no symptoms of acute tonsillitis and to a method of predicting the risk or the predisposition for recurrence of acute tonsillitis (RAT) in a subject having no symptoms of acute tonsillitis. These methods ae based on the determination of the biomarkers IL-1 ?, IL-18 and S100A8/S100A9 in said subject.Type: ApplicationFiled: June 6, 2019Publication date: August 12, 2021Inventors: Christoph Spiekermann, Thomas Vogl, Johannes Roth
-
Publication number: 20190374605Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subjectfor developing a NF-?B-associated postnatal inflammatory disorder.Type: ApplicationFiled: November 6, 2017Publication date: December 12, 2019Inventors: Dorothee Viemann, Johannes Roth, Thomas Vogl
-
Patent number: 10350315Abstract: The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.Type: GrantFiled: October 29, 2015Date of Patent: July 16, 2019Assignee: Westfaelische Wihelms-Universitaet MuensterInventors: Andreas Faust, Sven Hermann, Johannes Roth, Michael Schaefers, Thomas Vogl
-
Publication number: 20190185530Abstract: The present invention relates to mutants of S100A12 having at least one mutation in the high-affinity calcium binding hand or the low-affinity calcium binding hand or the zinc binding region. The present invention also relates to methods of detecting S100A12 dimers in a sample as well as methods of diagnosis using the S100A12 mutant of the invention, as well as to diagnostic compositions and kits comprising such an S100A12 mutant. The present invention further relates to a method of generating an antibody that specifically binds to an S100A12 dimer using the S100A12 mutant of the invention, as well as to an antibody that specifically binds to an S100A12 dimer.Type: ApplicationFiled: July 18, 2017Publication date: June 20, 2019Inventors: Johannes Roth, Thomas Vogi
-
Publication number: 20180017576Abstract: The present invention relates to a compound for use in a method of diagnosing acute or chronic inflammatory diseases in a subject. In particular, the present invention provides a S100A8/S100A9 heterodimer standard comprising at least one mutation in low- or high-affinity calcium binding hand that can be used in a method of detecting biomarkers of inflammation in a sample. Accordingly, the S100A8/S100A9 heterodimer standard allows for standardizing quantitative immunoassays and quantifying S100A8/S100A9 heterodimers.Type: ApplicationFiled: January 21, 2016Publication date: January 18, 2018Inventors: Johannes Roth, Thomas Vogl
-
Publication number: 20170333577Abstract: The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.Type: ApplicationFiled: October 29, 2015Publication date: November 23, 2017Inventors: Andreas Faust, Sven Hermann, Johannes Roth, Michael Schaefers, Thomas Vogl
-
Publication number: 20170138931Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measurType: ApplicationFiled: April 13, 2009Publication date: May 18, 2017Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTERInventors: JOHANNES ROTH, CLEMENS SORG
-
Publication number: 20160289270Abstract: Provided is an isolated peptide or a peptidomimetic comprising a sequence corresponding to amino acid positions 431-616 or 411-616 of the human protein TLR4 or corresponding to amino acid positions 84-131 of the human protein MD-2. Provided is also an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 411 to 616 of variant 1 the human protein TLR4. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 86 to 131 of the human protein MD2. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between one of the above peptides or whole molecules and an S100A8 or S100A9 or S100A8/S100A9 protein or a functional fragment thereof.Type: ApplicationFiled: November 17, 2014Publication date: October 6, 2016Applicant: Westfaelische Wilhelms-Universitaet MuensterInventors: Johannes Roth, Thomas Vogl
-
Publication number: 20150210768Abstract: Provided is an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 63-79 or 73-85 of the human protein S100A9. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 55-71 of the human protein S100A8. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between a peptide corresponding to one of the above epitopes of S100A9 or the above epitope of S100A8 and a TLR4 receptor, where a compound suspected to affect the complex formation is contacted with the peptide and the TLR4 receptor.Type: ApplicationFiled: September 10, 2013Publication date: July 30, 2015Inventors: Johannes Roth, Thomas Vogl
-
Publication number: 20150150910Abstract: The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 16, 2015Publication date: June 4, 2015Inventors: Jan EHRCHEN, Georg VARGA, Johannes ROTH, Cord SUNDERKOETTER
-
Patent number: 8817340Abstract: The invention relates to a large-format scanning system (1) comprising at least two image acquisition elements (2) in a cascade arrangement, at least one platen, preferably a glass plate (3), arranged upstream thereof, and at least two reflector rolls (5) arranged opposite the at least two image acquisition elements (2) in a cascade arrangement, said reflector rolls being pressed against the glass plate (3) and/or a copy (4) to be scanned by means of resilient elements (6) that are arranged at the sides of the reflector rolls (5). According to the invention, the side portions (7) of the reflector rolls (5) are designed such that they touch the glass plate (3) only outside the reading area of the image acquisition elements (2) for the copy to be scanned (4) and that the copy to be scanned (4) rests on the glass plate (3) in the center area (8) of the reflector rolls (5).Type: GrantFiled: April 18, 2012Date of Patent: August 26, 2014Assignee: Roth+Weber GmbHInventors: Johannes Roth, Gerd Ermert
-
Publication number: 20140029071Abstract: The invention relates to a large-format scanning system (1) comprising at least two image acquisition elements (2) in a cascade arrangement, at least one platen, preferably a glass plate (3), arranged upstream thereof, and at least two reflector rolls (5) arranged opposite the at least two image acquisition elements (2) in a cascade arrangement, said reflector rolls being pressed against the glass plate (3) and/or a copy (4) to be scanned by means of resilient elements (6) that are arranged at the sides of the reflector rolls (5). According to the invention, the side portions (7) of the reflector rolls (5) are designed such that they touch the glass plate (3) only outside the reading area of the image acquisition elements (2) for the copy to be scanned (4) and that the copy to be scanned (4) rests on the glass plate (3) in the center area (8) of the reflector rolls (5).Type: ApplicationFiled: April 18, 2012Publication date: January 30, 2014Inventors: Johannes Roth, Gerd Ermert
-
Publication number: 20130041349Abstract: The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 25, 2011Publication date: February 14, 2013Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTERInventors: Jan Ehrchen, Georg Varga, Johannes Roth, Cord Sunderkoetter
-
Publication number: 20050147972Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measurType: ApplicationFiled: February 17, 2003Publication date: July 7, 2005Inventors: Johannes Roth, Clemens Sorg
-
Publication number: 20030175713Abstract: Method for diagnosing inflammatory diseases, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, based on the marker Calgranulin C. The method comprises the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or connection of Calgranulin C polypeptide(s) and/or nucleic acids encoding the polypeptide(s) present in the biological sample; and (c) comparing the amount and/or concentration of Calgranulin C and/or nucleic acids encoding the polypeptide(s) determine to be in the biological sample with that of a corresponding control sample, wherein the difference in the amount of Calgranulin C and/or nucleic acids encoding the polypeptide(s) is indicative for the stages of the disease to be diagnosed.Type: ApplicationFiled: February 15, 2002Publication date: September 18, 2003Inventors: Clemens Sorg, Johannes Roth